much go morn amrn
gild/abbv qure ions/akca
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
holi smoke monday much newsher highlight see detail
alxn soliri knock park nmo studi ad new indic model
increas pt
amrn vascepa epa shockingli posit cvot trial patient elev tg
potenti implic nash space
launch author gener epclusa new competitor abbv mavyret
anab etokimab show posit result eosinophil asthma studi competitor
regn/sni dupix far behind
ions/akca lica-aso lp show strong efficaci clean safeti profil nv like
move start cvot possibl anoth faster path market
qure track hemophilia gene therapi
xon found way manufactur cannibinoid low cost
nite present gene therapi data xlrp
surprisingli strong result soliri nmo estim pt us ab nmo
us similar approv treatment altern extrem compel result abil
prevent relaps could prove one largest indic yet compani franchis
wouldnt give much increment color address market consid pursu
indic well
estim patient would elig studi roughli
patient use alxn epidemiolog data patient support literatur base
inclus criteria broader swath may suitabl treatment post-approv
prevent studi enrol patient least relaps last month
relaps last month least relaps month prior screen
studi primari endpoint time first adjud on-trial relaps show
reduct risk relaps soliri treat patient compar placebo
week treat patient relapse-fre compar
point refer despit run refractori patient popul myasthenia
gravi receiv broad label achr gmg patient
notenot add new indic soliri drive growth also make
harder competitor match label run compar nmo studi may difficult
given natur endpoint avail strong standard care soliri
could meaning increas outer year sticki soliri and/or
consensu estim august nmo low peak sale million
updat model reflect result announc today new estim
peak ww sale indic million net effect increas pt
addit drug develop nmo includ roch satralizumab antibodi
studi studi primari complet date octob initi proof
concept avail small studi tocilizumab actemra anoth antibodi
well test inebilizumab antibodi studi
amrn surpris everyon announc reduce-it result vascepa pure epa
eicosapentaeno acid reduc risk mace event p-valu
placebo-control cvot drug approv patient tg mg/dl show benefit
patient baselin tg establish cv diseas risk factor control
median baselin tg
note prior studi mix lovaza show cv benefit ascend trial
diabet patient without evid cv diseas normal tg
data present late breaker aha
compani said interest sell compani grow sale forc
promot
somewher implic nash fieldperhap give metabol activ
drug lower tg thrb agonist ppar stronger posit potenti
benefit larg cvot trial take mani year show vascepa
relev comparator/competitor note drug shown benefit fatti liver
gild author gener epclusa price close abbv mavyret interest strategi umer
profil medicare/medicaid potenti implic continu cure race bottom
hope preced cure
report result singl iv dose etokimab antibodi adult sever
eosinophil cells/ml asthma posit competit biolog potenti less frequent
vs dupix follow load dose note earli effect
increment benefit roughli ballpark regn/sni dupix azn fasenra
strong eosinophil lower
start etokimab eosinophil asthma next year atla pbo
control atop derm eclips pbo control trial rhinus nasal polyp
note regn/sni antibodi clinic develop
monotherapi potenti combo dupix result small pbo control studi
could avail come month data small pbo control studi
combo dupix avail next year
follow chart show eosinophil benefit etokimab benefit
dupix much longer studi differ time frame
ions/akca report posit result lica-aso lp test dose
present late-break aha
good background lp cv risk factor click lp independ risk factor
atherosclerosi aortic stenosi
patient high lp uln treat month strong efficaci platelet
signal seen central-lab confirm platelet incid platelet
drug placebo isr minor patient sound like rang
mostli mild drop
indic major pt achiev lp level dose respons seen
efficaci monthli dose
note prior studi shown dose-depend reduct lp
nv may opt-in end meet fda fee goe serv
yet anoth valid compel profil lica-conjug aso target
knockdown liver-produc protein expect start earli next year prepar
nv plan larg cvot studi could theori tri acceler approv high-risk
popul base lp biomark
qure track hemophilia gene therapi trial announc morn patient
treat vc/kg dose-confirm studi gene therapi
padua variant swap past month top-line data part hope-b
studi expect ye confirm dose portion alreadi recruit patient treatment
expect begin earli trial overal enrol pt includ observ lead-in
compani corpor present frame potenti activ expect amt-
xon- announc morn method produc low-cost cannabinoid rumbl bear
argument cbd expens make gwph narrow margin experi
sativex manag insist cog epidiolex pharma-lik xon
indic get cannabinoid yield cog interestingli xon use yeast strain
still believ epidiolex exclus driven primarili mix dozen
non-cbd cannabinoid difficult replic gener
morn day nite review result xiriu dose escal studi
provid detail accompani weekend press releas overal macular sensit
central loci sensit number respond db improv loci
present cohort pt per cohort efficaci
perspect cohort demonstr signific efficaci signal measur
microperimetri although respond higher dose cohort well
cohort efficaci signal may explain healthier patient compar rel cohort
cohort werent consist higher dose saw mild inflamm issu may
dampen efficaci effect nite state mechan place detect subtl
inflamm issu treat go forward restor efficaci remain seen
overal recept data updat poor stock still struggl interpret
aav gene therapi dataset retina indic xlrp gene therapi candid
includ one agtc/biib
valuat deriv valuat base dcf use discount rate
appli commerci stage biotech compani termin growth rate
reflect optimist outlook durabl compani franchis includ
product revenu reflect potenti busi develop
risk risk price target includ intensifi competit threat formid biopharma
compani along potenti amplifi price pressur failur build compel
develop pipelin stumbl develop trial would expect litani
downgrad substanti re-rat
valuat deriv pt dcf model use discount rate
slightli standard rate derisk compani reflect uncertainti outlook
spinraza termin growth reflect solid pipelin challeng revenu base grow
includ meaning contribut spinraza sale reach
declin gene therapi imping includ modest contribut ttr fap program
believ need platelet monitor tip market favor includ contribut
huntington sale reach includ meaning contribut
program lump catch basket deliv anoth revenu
plenti potenti driver relev factor ix antisens program bayer
develop prevent thrombosi esrd hemodialysi popul despit project
partner gener mani billion revenu captur
risk relev risk includ platform histor issu inflamm
thrombocytopenia develop pursu sub-optimal target deliveri approach regulatori
especi light certain drug side effect profil commerci particularli compani
propens outlicens program captur full valu
valuat deriv use dcf discount rate
termin growth rate discount rate standard rate appli across clinic stage compani
reflect believ appropri return sharehold termin growth rate also
standard coverag univers biolog compani long product live
risk qure highli depend success complet clinic trial secur regulatori approv
ultim achiev commerci success hemophilia gene therapi competit
establish treatment modal competitor gene therapi preclin candid employ
unproven moa clinic risk remain
valuat price target deriv dcf termin growth rate
line biolog focus smid cap compani earli product cycl discount
risk earli stage clinic compani candid face clinic regulatori commerci
risk particular improv result may seen pediatr earlier treat patient safeti
efficaci fall short seen preclin model
articl articl
time dissemin septemb et
analyst josh schimmer maneka mirchandaney ami liu shenston huang primarili respons prepar research
report attest follow view opinion render research report reflect person view
subject compani issuer part research analyst compens directli relat specif
recommend view research report
